Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.58 |
| ▸ | IL1RN | P18510 | 5/20 | 0.54 |
| ▸ | GHSR | Q92847 | 4/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.54 |
| ▸ | ECE1 | P42892 | 5/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496496 | 0.95 | GHSR (0.56) | GHSRECE1 | |
| SCHEMBL29378588 | 0.95 | ERAP2 (0.63) | ERAP2IL1RNGHSRERAP1ECE1 | |
| SCHEMBL31583852 | 0.95 | ERAP2 (0.63) | ERAP2IL1RNGHSRERAP1ECE1 | |
| SCHEMBL30929767 | 0.94 | ERAP2 (0.58) | ERAP2IL1RNGHSRERAP1ECE1 | |
| SCHEMBL30929763 | 0.94 | ERAP2 (0.58) | ERAP2IL1RNGHSRERAP1ECE1 | |
| SCHEMBL30093048 | 0.94 | GHSR (0.60) | GHSRECE1 | |
| SCHEMBL30093069 | 0.94 | EDNRA (0.59) | ERAP2IL1RNGHSRERAP1ECE1 | |
| SCHEMBL29684075 | 0.94 | ERAP2 (0.58) | ERAP2IL1RNGHSRERAP1ECE1 | |
| SCHEMBL30130563 | 0.93 | GHSR (0.59) | GHSRECE1 | |
| SCHEMBL30130571 | 0.93 | GHSR (0.59) | GHSRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | Nanjing Finepeptide Biopharmaceutical Co.,Ltd (CN) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150423-A1 | GLP-1 ANALOGUE-MODIFIED DIMERS WITH DIFFERENT CONFIGURATIONS, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN TREATMENT OF TYPE II DIABETES | GLP1R, IAPP, GCG | ERAP2 912/4885IL1RN 1890/4885GHSR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.